Prostatron receives panel go-ahead
This article was originally published in Clinica
Executive Summary
EDAP International's Prostatron was unanimously recommended for approval for the treatment of benign prostatic hypertrophy by an FDA panel on October 2Oth. The gastroenterology and urology devices advisory committee indicated that post-marketing follow-up should be performed on 100 patients for five years after surgery to ensure that no chronic complications develop. EDAP has the option of performing the extended follow-up on patients who were part of the clinical trials or on new patients.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.